Merck: positive results in certain lung cancers

(CercleFinance.com) - Merck announced this weekend that results from an interim analysis of an ongoing Phase 2 trial showed that ifinatamab deruxtecan (I-DXd) continued to demonstrate promising objective response rates in patients with pre-treated extended-stage small cell lung cancer (ES-SCLC).


Ifinatamab deruxtecan is an antibody-drug conjugate directed against B7-H3 (a membrane protein involved in the regulation of the immune system and often over-expressed in cancers) specially designed and discovered by Daiichi Sankyo and jointly developed by Daiichi Sankyo and Merck.

Small cell lung cancer (SCLC) is the second most common type of lung cancer, accounting for around 15% of cases.

Copyright (c) 2024 CercleFinance.com. All rights reserved.